Phatogenycs´ mechanisms in the Systemic Sclerosis
Keywords:
Systemic sclerosis, microkimerismAbstract
In the systemic sclerosis the same as in rest of the illnesses that correspond to the group of the Conectivitis their pathogeny it is not very established; in her it intervenes many factors like they are the genetic association, inheritance, environmental factors and inflammatory answer, their relationship with endogenous infections behaving from a special way to other inflammatory rheumatic illnesses. He/she is carried out a bibliographical revision of the inflammatory process that is developed in the systemic sclerosis as important part in the pathogenyc of the illness, with the objective of to obtain bigger knowledge on the same one and to interpret in a better way the form in which the same one is developed to be able to use more effective therapeutic outlines in the treatment of the systemic sclerosis.Downloads
References
Chakravarty E. Pre-disease pregnancy complications and systemic sclerosis: pathogenic or pre-clinical? 2012;14(1):102.
Milanetti F, Bucha J, Testori A, Burt RK. Autologous hematopoietic stem cell transplantation for systemic sclerosis. 2011;6(1):16-28.
Mouthon L, Bérezné A, Bussone G, Noël LH, Villiger PM, Guillevin L. Scleroderma renal crisis: a rare but severe complication of systemic sclerosis. 2011;40(2):84-91.
Dimitroulas T, Giannakoulas G, Karvounis H, Settas L, Kitas GD. Systemic sclerosis-related pulmonary hypertension: unique characteristics and future treatment targets. 2012;18(11):1457-64
Sfikakis PP, Papamichael C, Stamatelopoulos KS, Tousoulis D, Fragiadaki KG, Katsichti P, et al. Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. Arthritis Rheum. 2007;56(6):1985-93.
Alarcón Segovia D. Tratado hispanoamericano de Reumatología, volumen 2. Bogotá: Ed. Nomos S.A; 2006. p. 887-909.
Johnson SR, Brode SK, Mielniczuk LM, Granton JT. Dual therapy in IPAH and SSc-PAH. A qualitative systematic review. 2012;106(5):730-9
García de la Peña Lefebvre P. Aspectos clínicos novedosos en la esclerodermia. Reumatología Clínica. 2008;4 Suppl 1:S45-9.
Mouthon L, Rannou F, Bérezné A, Pagnoux C, Arène JP, Foïs E, Poiraudeau S. Development and validation of a scale for mouth handicap in systemic sclerosis: the Mouth Handicap In System Sclerosis scale (MHISS). Ann Rheum Dis. 2007;66(12):1651-5.
Arnaud L, Huart A, Plaisier E, Francois H, Mougenot B, Tiev K, et al. ANCA-related crescentic glomerulonephritis in systemic sclerosis: revisiting the “normotensive scleroderma renal crisis” Clin Nephrol. 2007;68(3):165-70.
Sfikakis PP, Papamichael C, Stamatelopoulos KS, Tousoulis D, Fragiadaki KG, Katsichti P, et al. Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. Arthritis Rheum. 2007;56(6):1985-93.
Barst RJ, Gibbs JSR, Ghofrani HA, Hoeper MM, McLaughlin VV, Rubin LJ, Galiè N. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. Journal of the American College of Cardiology. 2009;54(1):78-84.
Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med. 2007;176(10):1026-34.
Paone C, Chiarolanza I, Cuomo G, Ruocco L, Vettori S, Menegozzo M. Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low dose cyclophosphamide pulse therapy. Clin Exp Rheumatol. 2007;25(4):613-6.
Quillinan NP, Denton CP. Disease-modifying treatment in systemic sclerosis: current status. Current opinion in rheumatology. 2009;21(6):636-41.
Fertig N, Domsic R, Rodríguez- Reyna T, Kuwuana M, Lucas M, Medsger T, Karol JR, Li-Bostwick F Anti–U11/U12 RNP Antibodies in Systemic Sclerosis: A New Serologic Marker Associated With Pulmonary Fibrosis. 2009;61(7):958-65.
Leal Mursulí A, Rodríguez López E, Ramos Díaz N, Izquierdo Lara T, Adefna Pérez I. Esclerodermia como causa de sangramiento digestivo alto: A propósito de un caso. Rev Cubana cir [revista en Internet]. 2000 Abr [citado 25 jul 2014];39(1):82-4. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-74932000000100012&lng=es.
Barriga Oropeza J, Murillo Sanchez C, Agreda Guerrero J. Esclerodermia o esclerosis sistémica. A propósito de un caso. Rev. bol. ped. [revista en Internet]. 2003 [citado 3 julio 2014];42(2):97-9. Disponible en: http://www.scielo.org.bo/scielo.php?pid=S102406752003000200004&script=sci_abstract
Mustelier JV, Cabrera Rego JO, García Fernández R, López Mantecón AM. Miocardiopatía restrictiva y comunicación interauricular en un paciente con esclerodermia. Rev cubana med [revista en Internet]. 2010 Sep [citado 16 mayo 2014];49(3):275-81. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75232010000300007&lng=es
Romero-González A, Gil-Agramonte M, Ortiz-Labrada A, Tamayo-Rodríguez M, Álvarez Vladimir F, Suárez-Castillo JC, et al . Síndrome de Evans Fisher asociado con esclerodermia. Rev Cubana Hematol Inmunol Hemoter [revista en Internet]. 2014 Mar [citado 16 mayo 2014];30(1):81-8. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-02892014000100011&lng=es
Leal Mursulí A, Rodríguez López E, Ramos Díaz N, Izquierdo Lara FT, Adefna Pérez RI. Esclerodermia como causa de sangramiento digestivo alto: A propósito de un caso. Rev Cubana cir [revista en Internet]. 2000 Abr [citado 16 mayo de 2014];39(1):82-4. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-74932000000100012&lng=es
Kashif M, Qureshi A , Adil SN, Khurshid M. Successful use of Rituximab in Evans syndrome and refractory immune thrombocytopenic purpura. J Pak Med Assoc. 2010;60(1):64-5.
Valentini G, Cuomo G, Abignano G, Petrillo A, Vettori S, Capasso A, Santoriello C. Early systemic sclerosis: assessment of clinical and pre-clinical organ involvement in patients with different disease features. Rheumatology. 2011;50(2):317-23.
Allanore Y, Meune C, Kahan A. Systemic sclerosis and cardiac dysfunction: evolving concepts and diagnostic methodologies. Curr Opin Rheumatol. 2008;20(6):697-702.
Leitão de MN, Azevedo Edda MT, Bernardini EF, Salles F, Heinzmann F, Marconde T, Mello, Rios Gomes BE. CysLT1 receptor inhibition in patients with Raynaud's phenomenon: capillaroscopic evidence of the role of leukotriene. Rev. Bras. Reumatol. 2012;52(1):30-2.
Martins TC, Fernandes Adan RF. Autoimmune thyroid disease in patients with rheumatic diseases. Rev. Bras. Reumatol. 2012;52(3):423-30.
Correia Leite C; Costa Maia A. Symptoms of disease and psychological adaptation in Brazilian scleroderma patients. Rev. Bras. Reumatol. 2013;53(5):405-11.
Gerent Petry D, Len CA, Esteves MO, Ramos Ascensão MT. Nailfold capillaroscopy in children and adolescents with rheumatic diseases. Rev. Bras. Reumatol. 2012;52(5):727-32.
Published
How to Cite
Issue
Section
License
Warning of rights of author
The authors that publish in this journal agree with the following terms:
The authors conserve the rights of author and concede to the journal the right of the first publication, fulfilling with the license Creative Commons Attribution License that allows to others share the work with recognition of the authorship of their articles, and the initial publication in this journal.
The authors can establish separately additional agreements for the no exclusive distribution of the version of the work published in the journal (for example, situate it in an institutional repository, in a personal blog or publish it partial or totally in a book), with a recognition of their initial publication in this journal.
To be able to send the manuscript or part of him passed three months of published, for his evaluation to other publishers, identifying it or not with the same title; whenever allusion is made to our journale and know it the new publisher.
The publishing committee of the Cuban Journal of Rheumatology authorizes to other publishers, to reproduce the articles published in our magazine, whenever it indicate the origin of the same.
The authors should send a document in Office Word application format through the electronic address of the magazine with a similar format to that we include next:
---------------------------------------------------------------------------------------------------------------------
Statement of authorship and cede of articles for the publication of the scientific work in the Cuban Journal of Rheumatology
Date:
Those who subscribe certify that are the authors of the work:
Of this form communicate the originality of our article clearing that the concepts and knowledges of other authors that have included in the text of the article, have been quoted properly in the bibliography.
We do proof besides that the article in question is original and has not been published, total neither partially, in another journal.
To be approved for his publication in the Cuban Journal of Rheumatology, do secession of the rights of publication to the same one through the method that realizes it usually.
In front of any catchword that exist by the article that send to evaluate, relieve of of the responsibility to the Cuban Journal of Rheumatology holding us responsible with all the difficulties that can berelated by any situation.
We include to continuation the name and the signature of all authors and collaborators of this article.
Name: Signature:
